Diamile A. Tavarez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diamile A. Tavarez has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Dingcheng Gao
Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, USA
1 shared publication Divya Ramchandani
Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, USA
1 shared publicationJustin R. Cross
Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publication- Linda T. Vahdat
Department of Medicine, Dartmouth Cancer Center, Lebanon, NH, USA
1 shared publication - Matthew M. Miele
Proteomics Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
1 shared publication - Mirela Berisa
Metabolomics Core, Shared Research Resources, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 15 December 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-16
Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis
Copper serves as a co-factor for a host of metalloenzymes that contribute to malignant progression. The orally bioavailable copper chelating agent tetrathiomolybdate (TM) has been associated with a significant survival benefit in high-risk triple negative breast cancer (TNBC) patients. Despite these promising data, the mechanisms by which copper depletion impacts metastasis are poorly understood and this remains a major barrier to advancing TM to a randomized phase II trial. Here, using two independent TNBC models, we report a discrete subpopulation of highly metastatic SOX2/OCT4+ cells within primary tumors that exhibit elevated intracellular copper levels and a marked sensitivity to TM. Global proteomic and metabolomic profiling identifies TM-mediated inactivation of Complex IV as the primary metabolic defect in the SOX2/OCT4+ cell population. We also identify AMPK/mTORC1 energy sensor as an important downstream pathway and show that AMPK inhibition rescues TM-mediated loss of invasion. Furthermore, loss of the mitochondria-specific copper chaperone, COX17, restricts copper deficiency to mitochondria and phenocopies TM-mediated alterations. These findings identify a copper-metabolism-metastasis axis with potential to enrich patient populations in next-generation therapeutic trials.
- 15 December 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-16
Top Cited PapersOpen AccessCopper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis
Copper serves as a co-factor for a host of metalloenzymes that contribute to malignant progression. The orally bioavailable copper chelating agent tetrathiomolybdate (TM) has been associated with a significant survival benefit in high-risk triple negative breast cancer (TNBC) patients. Despite these promising data, the mechanisms by which copper depletion impacts metastasis are poorly understood and this remains a major barrier to advancing TM to a randomized phase II trial. Here, using two independent TNBC models, we report a discrete subpopulation of highly metastatic SOX2/OCT4+ cells within primary tumors that exhibit elevated intracellular copper levels and a marked sensitivity to TM. Global proteomic and metabolomic profiling identifies TM-mediated inactivation of Complex IV as the primary metabolic defect in the SOX2/OCT4+ cell population. We also identify AMPK/mTORC1 energy sensor as an important downstream pathway and show that AMPK inhibition rescues TM-mediated loss of invasion. Furthermore, loss of the mitochondria-specific copper chaperone, COX17, restricts copper deficiency to mitochondria and phenocopies TM-mediated alterations. These findings identify a copper-metabolism-metastasis axis with potential to enrich patient populations in next-generation therapeutic trials.